Evidence map›Paper›PMID 40397390›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

DeepCCDS: Interpretable Deep Learning Framework for Predicting Cancer Cell Drug Sensitivity through Characterizing Cancer Driver Signals.

Jiashuo Wu, Jiyin Lai, Xilong Zhao, Ziyi Wang, Yongbao Zhang, Liqiang Wang, Yinchun Su, Yalan He, Siyuan Li, Ying Jiang and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiashuo WuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.ORCID https://orcid.org/0009-0002-8126-1984
Jiyin LaiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Xilong ZhaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Ziyi WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yongbao ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Liqiang WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yinchun SuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yalan HeCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Siyuan LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Ying JiangCollege of Basic Medical Science, Heilongjiang University of Chinese Medicine, Harbin, 150040, China.
Junwei HanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.ORCID https://orcid.org/0000-0002-3276-0819

Funding

National Natural Science Foundation of China 62 072 145National Natural Science Foundation of China 62 372 143Natural Science Foundation of Heilongjiang Province LH2019C042
6 · The paper itself

Abstract

Accurate characterization of cellular states is the foundation for precise prediction of drug sensitivity in cancer cell lines, which in turn is fundamental to realizing precision oncology. However, current deep learning approaches have limitations in characterizing cellular states. They rely solely on isolated genetic markers, overlooking the complex regulatory networks and cellular mechanisms that underlie drug responses. To address this limitation, this work proposes DeepCCDS, a Deep learning framework for Cancer Cell Drug Sensitivity prediction through Characterizing Cancer Driver Signals. DeepCCDS incorporates a prior knowledge network to characterize cancer driver signals, building upon the self-supervised neural network framework. The signals can reflect key mechanisms influencing cancer cell development and drug response, enhancing the model's predictive performance and interpretability. DeepCCDS has demonstrated superior performance in predicting drug sensitivity compared to previous state-of-the-art approaches across multiple datasets. Benefiting from integrating prior knowledge, DeepCCDS exhibits powerful feature representation capabilities and interpretability. Based on these feature representations, we have identified embedding features that could potentially be used for drug screening in new indications. Further, this work demonstrates the applicability of DeepCCDS on solid tumor samples from The Cancer Genome Atlas. This work believes integrating DeepCCDS into clinical decision-making processes can potentially improve the selection of personalized treatment strategies for cancer patients.

Indexed as

Antineoplastic AgentsDeep LearningNeoplasmsCell Line, TumorHumansNeural Networks, ComputerAntineoplastic Agentsdeep learningdrug sensitivityfeature representationprecision oncologyself‐supervised neural network

Identifiers

PMID40397390
PMCPMC12199323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.